Nama's AI scorecard currently rates Alignment Healthcare Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ALHC's P/E ratio?

Alignment Healthcare trades at a trailing price-to-earnings ratio of 14.1.

When does ALHC report earnings?

Alignment Healthcare's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.17.

What is the ALHC price target?

The median analyst price target from 12 analysts is $10.00, with a range of $8.00 – $17.00.

Is ALHC Shariah compliant?

Nama's AAOIFI-style screen reads Alignment Healthcare as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Alignment Healthcare (ALHC)

Healthcare · Healthcare Plans · NASDAQ

Alignment Healthcare (ALHC) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $1.54B, a trailing price-to-earnings ratio of 14.1 and a free-cash-flow yield of 7.8%. Over the most recent reported fiscal year, revenue grew 46.1%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -48.1% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-70.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.54B
Trailing P/E	14.1
Price / book	5.7
Price / sales	0.3
FCF yield	7.8%
Dividend yield	—
Gross margin	12.8%
Operating margin	1.9%
Net margin	1.5%
Revenue growth (YoY)	+46.1%
Revenue growth (3-yr annual)	+40.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Healthcare Plans

ALHC earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.17). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.05	$0.04	+25.0%	$1.36B
Q2 2026	Jul 30, 2026	$0.25	$0.20	+25.0%	$1.34B
Q1 2026	Apr 30, 2026	$0.12	$0.09	+33.3%	$1.24B
Q3 2025	Oct 30, 2025	$0.10	-$0.01	+1100.0%	$993.70M

ALHC analyst price target

Median target $10.00 from 12 analysts, ranging $8.00 – $17.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
ELV	Elevance Health	$91.96B	14.0
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
CNC	Centene	$34.53B	13.2
MOH	Molina Healthcare	$10.87B	104.5
OSCR	Oscar Health	$9.46B	12.7

Explore live ALHC data on Nama Insights →

ALHC FAQ

Is ALHC a buy?: Nama's AI scorecard currently rates Alignment Healthcare Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ALHC's P/E ratio?: Alignment Healthcare trades at a trailing price-to-earnings ratio of 14.1.
When does ALHC report earnings?: Alignment Healthcare's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.17.
What is the ALHC price target?: The median analyst price target from 12 analysts is $10.00, with a range of $8.00 – $17.00.
Is ALHC Shariah compliant?: Nama's AAOIFI-style screen reads Alignment Healthcare as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.